OOIR: Observatory of International Research

Papers

(The H4-Index of JHEP Reports is 36. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Non-alcoholic fatty liver disease: A patient guideline	131
NAFLD and liver transplantation: Disease burden, current management and future challenges	113
Lipid alterations in chronic liver disease and liver cancer	107
Treatment of NAFLD with intermittent calorie restriction or low-carb high-fat diet – a randomised controlled trial	100
Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors	93
Acute-on-chronic liver failure: Definitions, pathophysiology and principles of treatment	93
New targets for NAFLD	92
Epidemiology of non-alcoholic fatty liver disease and hepatocellular carcinoma	84
Artificial intelligence in liver diseases: Improving diagnostics, prognostics and response prediction	80
Organoids to model liver disease	78
Portal hypertension in cirrhosis: Pathophysiological mechanisms and therapy	77
ALBI grade: Evidence for an improved model for liver functional estimation in patients with hepatocellular carcinoma	77
Single-cell RNA sequencing of human liver reveals hepatic stellate cell heterogeneity	70
Novel vectors and approaches for gene therapy in liver diseases	61
Epigenetics in hepatocellular carcinoma development and therapy: The tip of the iceberg	59
Contribution of sarcopenia and physical inactivity to mortality in people with non-alcoholic fatty liver disease	59
Gut dysbiosis as a driver in alcohol-induced liver injury	58
Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B	56
NAFLD and MAFLD as emerging causes of HCC: A populational study	56
Impact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence area	50
Understanding the cellular interactome of non-alcoholic fatty liver disease	46
Adverse muscle composition is linked to poor functional performance and metabolic comorbidities in NAFLD	45
Potent suppression of hydrophobic bile acids by aldafermin, an FGF19 analogue, across metabolic and cholestatic liver diseases	43
The ALBI score: From liver function in patients with HCC to a general measure of liver function	42
Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease	41

Cell of origin in biliary tract cancers and clinical implications	41
Our emerging understanding of the roles of long non-coding RNAs in normal liver function, disease, and malignancy	39
Primary liver cancer in the UK: Incidence, incidence-based mortality, and survival by subtype, sex, and nation	38
The burden of non-alcoholic steatohepatitis: A systematic review of health-related quality of life and patient-reported outcomes	37
Exposure to perfluoroalkyl substances and risk of hepatocellular carcinoma in a multiethnic cohort	37
Assessing the impact of COVID-19 on liver cancer management (CERO-19)	37
Approach to the patient with acute severe autoimmune hepatitis	37
Controlled underdilation using novel VIATORR® controlled expansion stents improves survival after transjugular intrahepatic portosystemic shunt implantation	37
Real-world experience with obeticholic acid in patients with primary biliary cholangitis	37
De novo synthesis of hepatitis B virus nucleocapsids is dispensable for the maintenance and transcriptional regulation of cccDNA	37
The role of cGAS-STING signalling in liver diseases	36
Aramchol downregulates stearoyl CoA-desaturase 1 in hepatic stellate cells to attenuate cellular fibrogenesis	36